menu
    • menu
    [{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic T Cell Progenitors","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Not Applicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic T-cell Progenitor","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Not Applicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SMART101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Not Applicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Allogeneic T-cell Progenitor","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Smart Immune \/ European Innovation Council","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ European Innovation Council"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Allogeneic T-cell Progenitor","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Smart Immune \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SMART101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Not Applicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic T-cell Progenitors","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Not Applicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic T-cell Progenitor","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Not Applicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Seqens","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Allogeneic T-cell Progenitors","moa":"","graph1":null,"graph2":null,"graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Smart Immune \/ Smart Immune","highestDevelopmentStatusID":null,"companyTruncated":"Smart Immune \/ Smart Immune"}]

    Find Clinical Drug Pipeline Developments & Deals by Smart Immune

    Menu

    Smart Immune

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic T-cell Progenitors

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Seqens

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Smart Immune & CELLforCURE by SEQENS Partner for SMART101 Clinical Manufacturing

                            Details : The partnership aims to advance the clinical development of SMART101 an innovative therapy for patients with acute leukemia or primary immunodeficiencies (PID), in the EU and the US.

                            Brand Name : SMART101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Allogeneic T-cell Progenitors

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Seqens

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic T-cell Progenitor

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Smart Immune Announces Recommended SMART101 Dose for Adult Cancer Proof-of-Concept Trials

                            Details : SMART101 is an allogeneic cell therapy produced from healthy donor mobilized peripheral blood stem cells differentiated into T cell progenitors. It is being evaluated for hematological malignancies.

                            Brand Name : SMART101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 23, 2024

                            Lead Product(s) : Allogeneic T-cell Progenitor

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic T-cell Progenitors

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Smart Immune Treats Acute Leukemia Patient in Phase I/II ReSET-02 Trial

                            Details : SMART101 is an allogeneic cell therapy from healthy donor stem cells (CD34+) that differentiate into T cell progenitors, under evaluation for hematological malignancies.

                            Brand Name : SMART101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 02, 2024

                            Lead Product(s) : Allogeneic T-cell Progenitors

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SMART101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Two Leukemia Patients Received Smart Immune's SMART101 Therapy in Phase I/II ReSET-02 Trial

                            Details : SMART101 injection is generated ex vivo from allogeneic bloodstem cells, using Smart Immune’s ProTcell T-cell therapy platform, which is investigated for the treatment of adult acute leukemia and myelodysplasia syndrome.

                            Brand Name : SMART101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 27, 2023

                            Lead Product(s) : SMART101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic T-cell Progenitor

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Smart Immune Receives $5 Million Investment To Further Its Thymus-empowered Protcell Therapy Platform

                            Details : The new funding will advance a Phase 1/2 clinical trial of an innovative T-cell therapy, SMART101 (allogeneic T-cell progenitor) to treat cancer and infectious disease.

                            Brand Name : SMART101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 17, 2023

                            Lead Product(s) : Allogeneic T-cell Progenitor

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic T-cell Progenitor

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : European Innovation Council

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Smart Immune Receives €2.5m Grant and €15m Equity Investment Commitment from the European Innovation Counc...

                            Details : The net proceeds will accelerate the development of ProTcell to treat life-threatening cancers and infection. ProTcell introduces potent, allogeneic T-cell progenitors, SMART101, which are then differentiated by the thymus into fully functional T-cells.

                            Brand Name : SMART101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Allogeneic T-cell Progenitor

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : European Innovation Council

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SMART101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            1st Leukemia Patient Dosed With SMART101 at MSK

                            Details : SMART101 is generated ex vivo from allogeneic bloodstem cells, using Smart Immune’s ProTcell T-cell therapy platform. Once injected, SMART101 human T-cell progenitors travel to the thymus where they are educated to become fully functional and self-tole...

                            Brand Name : SMART101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 23, 2023

                            Lead Product(s) : SMART101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic T-cell Progenitor

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy P...

                            Details : The Smart Immune ProTcell™ platform generates allogenic T-cell progenitors that provide fully functional polyclonal T-cells within 3 months through thymic education.

                            Brand Name : SMART101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 20, 2022

                            Lead Product(s) : Allogeneic T-cell Progenitor

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed

                            Smart Immune

                            France arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic T Cell Progenitors

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart...

                            Details : Smart-101 ProTcells will be cultured from the same donor from whom the patient has received the initial CD34+ HSCT. This trial will rely upon a prospectively generated control database of AML/ALL patients who undergo routine HSCT’s at MSK.

                            Brand Name : Smart-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 13, 2021

                            Lead Product(s) : Allogeneic T Cell Progenitors

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth